Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses

Journal of Veterinary Internal Medicine

Volumn 18, Issue 2, 2004, Pages 231-237

  Gardner, Sarah Y ^a   Atkins, Clarke E ^a   Sams, Richard A ^b   Schwabenton, A Brooke ^a   Papich, Mark G ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

ACE; Aldosterone; Angiotensin; Blood pressure; Enalaprilat; Renin

Indexed keywords

ANGIOTENSIN I; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LACTIC ACID;

ARTICLE; BLOOD GAS; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HEART RATE; MEAN ARTERIAL PRESSURE; NASOGASTRIC TUBE; NONHUMAN; POTASSIUM BLOOD LEVEL; VENOUS BLOOD;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AREA UNDER CURVE; BLOOD CHEMICAL ANALYSIS; BLOOD GAS ANALYSIS; BLOOD PRESSURE; ENALAPRIL; ENALAPRILAT; FEMALE; HEART RATE; HORSES; INFUSIONS, INTRAVENOUS; PEPTIDYL-DIPEPTIDASE A;

EQUIDAE;

EID: 1642265317     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<231:COTPAP>2.0.CO;2     Document Type: Article

References (43)

1. CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435.
2. IMPROVE Study Group. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: Results of invasive multicenter prospective veterinary evaluation of enalapril study. J Vet Intern Med 1995;9:234-242.
3. Cove Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the cooperative veterinary enalapril study group. J Vet Intern Med 1995;9:243-252.
4. LIVE Study Group. Effects of enalapril maleate on survival in dogs with naturally acquired heart failure: Results of the long-term investigation of veterinary enalapril (LIVE) study group. J Am Vet Med Assoc 1998;13:1573-1577.
5. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
6. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
7. The Bench Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:5-18.
8. Hamlin RB, Benitz AM, Ericsson GF, et al. Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. J Vet Intern Med 1996;10:85-87.
9. Brown NJ, Vaughn DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-1420.
10. Tillman LG, Moore JN. Serum angiotensin converting enzyme activity and response to angiotensin I in horses. Equine Vet J 1989; 7(Suppl):80-83.
11. Muir WM, Sams RA, Hubbell JAE, et al. Effects of enalaprilat on cardiorespiratory, hemodynamic, and hematologic variables in exercising horses. Am J Vet Res 2001;62:1008-1013.
12. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
13. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York, NY: Marcel Dekker; 1982.
14. Campbell MJ, Machin D. Non-parametric tests. In: Campbell MJ, Machin D, eds. Medical Statistics - A Commonsense Approach, 3rd ed. Chichester, UK: J Wiley & Sons Ltd; 1999:163-165.
15. Tan L-B, Jalil JE, Pick R, et al. Cardiac myocytic necrosis induced by angiotensin II. Circ Res 1991;69:1185-1195.
16. Atkins CE, Brown WA, Coats JR, et al. Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation. J Am Vet Med Assoc 2002;221:654-658.
17. Davis JL, Gardner SY, Schwabenton AB, Breuhaus B. Congestive heart failure in horses: 14 cases (1984-2001). J Am Vet Med Assoc 2002;220:1512-1515.
18. Parry BW. Resting blood pressure values in various equine clinical cases. J Equine Vet Sci 1984;4:49-56.
19. Grauer GF, Creco DS, Getzy DM, et al. Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis. J Vet Intern Med 2000;14:526-533.
20. Maschio G, Alberti D, Gerard J, et al. Effect of the angiotensin- converting enzyme-inhibitor benazepril on the progression of chronic renal failure. N Engl J Med 1996;334:939-945.
21. Sleeper MM. Myocardial disease. In: Robinson NE, ed. Current Therapy in Equine Medicine 5. Philadelphia, PA: WB Saunders; 2003: 620-621.
22. Allen D, Moore JN, Clark ES, Prasse KW. Evaluation of equine Starling forces and hemodynamics during early laminitis. Am J Vet Res 1990;51:1930-1934.
23. Moore JN, Allen D, Clark SE. Pathophysiology of acute laminitis. Equine Pract 1991;13:29-31.
24. Moore JN, Allen D. A Guide to Acute Equine Laminitis. Trenton, NJ: Veterinary Learning Systems; 1995;1-40.
25. Amoss MS, Hood DM, Williams JD, et al. Concentrations of plasma catecholamines, serum aldosterone, and plasma renin activity following induced laminitis in the horse. Southwest Vet 1988;38:16-25.
26. Harkema JR, Robinson NE, Scott JB. Cardiovascular, acid-base, and plasma volume changes in ponies developing alimentary laminitis. Am J Vet Res 1978;39:741-744.
27. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-1525.
28. Hinckley KA, Fearn S, Howard BR, Henderson IW. Nitric oxide donors as treatment for grass induced acute laminitis in ponies. Equine Vet J 1996;28:17-28.
29. Biollaz J, Schelling JL, Jacot Des Combes B, et al. Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol 1985;14:363-368.
30. Ulm EH, Hichens M, Gomez HJ, et al. Enalapril maleate and a lysine analogue (MK-521): Disposition in man. Br J Clin Pharmacol 1982;14:357-362.
31. MacFadyen RJ, Meredith PA, Elliott HL. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1993;25:274-282.
32. Till AE, Gomez HJ, Hichens M, Bolognese JA. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos 1984;5:273-280.
33. Meredith PA, Donnelly R, Elliott HL, et al. Prediction of the antihypertensive response to enalapril. J Hypertens 1990;8:1085-1090.
34. Reid JL, Meredith PA. Concentration-effect analysis of antihypertensive drug responses. Hypertension 1990;16:12-18.
35. Donnelly R, Meredith PA, Elliott HL, Reid JL. Kinetic-dynamic relations and individual responses to enalapril. Hypertension 1990;15: 301-309.
36. Toutain PL, Lefebvre HP, Laroute V. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: Case of enalapril and benazepril in dogs. J Pharmacol Exp Ther 2000;292:1094-1103.
37. Toutain PL, Lefebvre HP, King JN. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. J Pharmacol Exp Ther 2000;292:1087-1093.
38. Abrams WB, Davies RO, Gomez HJ. Clinical pharmacology of enalapril. J Hypertens 1984;2:31-36.
39. Shoback DM, Williams GH, Swartz SL, et al. Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol 1983;5: 1010-1018.
40. MacGregor GA, Markandu ND, Bayliss J, et al. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): Evidence for role of renin system in normotensive subjects. Br Med J 1981;283:401-403.
41. Millar JA, Derkx FHM, McLean K, Reid JL. Pharmacodynamics of converting enzyme inhibition: The cardiovascular, endocrine and autonomic effects of MK421 (Enalapril) and MK521. Br J Clin Pharmacol 1982;14:347-355.
42. Davies RO, Gomez HJ, Irvin JD, Walker JF. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984;18: 215S-229S.
43. Biollaz J, Burnier M, Turini GA, et al. Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther 1981;29:665-670.